AVXL Live signals | Maximize Profits with Getagraph.com

SELL 159090 min ago

@ $5.61

Issued: 13 Feb 2024 @ 15:41

Return: -27.63%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: -3.28 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases...

Stats
Today's Volume	2.55M
Average Volume	1.25M
Market Cap	343.64M
EPS	$0 ( 2024-05-09 )
Next earnings date	( $-0.130 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.12
ATR14	$0.00600 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-15	Thomas Steffen	Buy	5 000	Common Stock
2024-03-28	Missling Christopher U	Buy	73 380	Common Stock
2024-03-28	Missling Christopher U	Sell	73 380	Common Stock
2024-03-28	Missling Christopher U	Sell	73 380	Stock Option (Right to Buy)
2024-02-20	Donhauser Peter D.o.	Buy	50 000	Stock Option (Right to Buy)

INSIDER POWER
2.94
Last 100 transactions
Buy: 6 191 471 \| Sell: 2 192 392

Volume Correlation

Long: -0.45 (neutral)

Short: -0.05 (neutral)

Signal:(37.413) Neutral

Anavex Life Sciences Corp Correlation

10 Most Positive Correlations
OZEM	1
AKTX	0.949
FXNC	0.948
ADTN	0.941
HAIN	0.939
TRVN	0.937
SIRI	0.935
OSUR	0.932
HTLD	0.932
LUCD	0.93

10 Most Negative Correlations
SWAV	-0.933
PWP	-0.932
JVA	-0.929
MTEK	-0.927
RZLT	-0.926
FANG	-0.924
APXI	-0.921
VNOM	-0.917
GBDC	-0.913
FTGC	-0.904

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Anavex Life Sciences Corp Correlation - Currency/Commodity

0.45
( neutral )

0.46
( neutral )

0.00
( neutral )

0.18
( neutral )

0.16
( neutral )

Anavex Life Sciences Corp Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.600

FY	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.600

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.620

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.540

Financial Reports:

No articles found.

Anavex Life Sciences Corp Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.